TLR7

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, DTRA, Conditional sentence, Inflammation, Viral, Marburg virus disease, Human, TLR7, Therapy, Lassa mammarenavirus, Lassa fever, Bleeding, Toll-like receptor 7, Vaccine

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.
  • The objective of the program is to evaluate the efficacy of PRTX007 in a series of animal models for Lassa fever and establish an effective treatment method of Lassa virus in humans.
  • “Primmune has demonstrated broad spectrum antiviral activity with PRTX007 and with related compounds from our discovery and development program,” said Charlie McDermott, President, Chief Executive Officer and Director of Primmune Therapeutics.
  • “PRTX007’s novel immunologic approach has the potential for combination use with direct acting anti-viral agents – enabling widely applicable utility in the treatment of Lassa fever and other hemorrhagic viruses.”

Primmune Therapeutics Presents Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Retrieved on: 
Friday, November 10, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Greater Mauritania, Hepatology, Safety, Annual general meeting, Therapy, Aes, Hepatitis B virus, Headache, AASLD, SAD, IL-6, Patient, HBV, QOD, TLR7, Pharmacokinetics, Liver, Messenger, Half-life, Șaeș, NK, Vaccine

The data presented highlight the suitability of PRTX007 for investigation as a combination therapy for curative treatment of chronic hepatitis B virus (HBV) infection.

Key Points: 
  • The data presented highlight the suitability of PRTX007 for investigation as a combination therapy for curative treatment of chronic hepatitis B virus (HBV) infection.
  • Data show that PRTX007 demonstrated a favorable safety profile in all of the analyzed cohorts with no serious adverse events (SAEs) observed.
  • “We are encouraged by the results of this Phase 1 study which demonstrate the safety and tolerability of PRTX007 administration in healthy volunteers.
  • CD8+ T cells and NK cell activation (CD38+ markers) increased markedly from pretreatment to end of dosing in all HVs.

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Retrieved on: 
Wednesday, October 11, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Annual general meeting, TLR7, Therapy, Liver, Hepatitis B virus, AASLD, Hepatology, HBV, Vaccine

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced the upcoming presentation of new clinical data from its Phase 1 study of PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting).

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced the upcoming presentation of new clinical data from its Phase 1 study of PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting).
  • The poster presentation will highlight the suitability of PRTX007 for investigation in combination therapy for curative treatment of chronic hepatitis B virus (HBV) infection.
  • The Liver Meeting will be held in Boston from November 10-14.
  • Title: Clinical validation of an orally-delivered, systemically activated TLR7 agonist to boost host immune response to chronic viral diseases, including hepatitis B virus

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

Retrieved on: 
Thursday, June 29, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Janus, TLR7, Drug development, Pfizer, Therapy, PIPE, FAP, Science, Jack Barchas, Acquisition, Investment, Purdue University, Mab, ADC, FDA, Pharmaceutical industry, Management, Immunome, Seagen

Clay B. Siegall, Ph.D., who was appointed CEO and President of Morphimmune earlier this year, will serve as the CEO, President, and Chairman of the Board of Directors of Immunome.

Key Points: 
  • Clay B. Siegall, Ph.D., who was appointed CEO and President of Morphimmune earlier this year, will serve as the CEO, President, and Chairman of the Board of Directors of Immunome.
  • Dr. Siegall previously served as the CEO and President of Seagen, Inc., which he co-founded in July 1997.
  • During his tenure, he raised well over $1 billion of financing for Seagen from public and private markets and oversaw the company’s acquisition of Cascadian Therapeutics.
  • Both the merger and private placement are expected to close by the end of Q4 2023.

Lupus Research Alliance Honors Carola Vinuesa, MD, PhD, for Discovering a Specific Gene Variant that Causes Lupus in Some Patients

Retrieved on: 
Thursday, June 22, 2023
Francis Crick Institute, Mouse, TLR7, Lupus Research Alliance, Weill Cornell Medicine, Guanosine, Toll-like receptor 7, Prevalence, Genetics, Federation of Clinical Immunology Societies, Attention deficit hyperactivity disorder predominantly inattentive, Australian Academy of Science, Medical Research Council, Mutation, Cas9, Research, SLE, Gottschalk Medal, Lupus, RNA, National Health and Medical Research Council, Doctor of Philosophy, Government, Autoimmunity, Assistant, FAA, The Prize, X chromosome, National Health, Patient, FRS, Immune system, Diagnosis, Bacteria, Royal Society, NHMRC, Genome, Autoantibody, Disease, Pharmaceutical industry, Vaccine, Science, MD

The Lupus Research Alliance awarded its 2023 Lupus Insight Prize to Carola Vinuesa, MD, PhD, of The Francis Crick Institute.

Key Points: 
  • The Lupus Research Alliance awarded its 2023 Lupus Insight Prize to Carola Vinuesa, MD, PhD, of The Francis Crick Institute.
  • Many lupus patients display increased TLR7 activity; however, disease-causing mutations in the TLR7 gene had not been identified.
  • "I am honored to receive this most prestigious award from the Lupus Research Alliance in recognition of our discovery of a genetic cause of lupus.
  • To determine whether the TLR7 mutation identified causes lupus, Dr. Vinuesa's team used a gene-editing tool, CRISPR/Cas9, to introduce the specific variant into mice.

Primmune Therapeutics to Present at the 2023 STING & TLR-Targeting Therapies Summit

Retrieved on: 
Monday, May 8, 2023
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, TLR7, Therapy, Summit, Pharmacology, Vaccine

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and to clear human papillomavirus and related pre-cancerous cervical lesions, today announced that Primmune’s Senior Vice President & Chief Scientific Officer James Appleman, Ph.D., will present at the 4th STING & TLR-Targeting Therapies Summit being held in Boston, Massachusetts from May 9-11, 2023.

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and to clear human papillomavirus and related pre-cancerous cervical lesions, today announced that Primmune’s Senior Vice President & Chief Scientific Officer James Appleman, Ph.D., will present at the 4th STING & TLR-Targeting Therapies Summit being held in Boston, Massachusetts from May 9-11, 2023.
  • The presentation at the Summit will also review how PRX034, the TLR7 agonist systemically delivered by PRTX007, has been shown to induce engagement of the innate and adaptive immune responses while avoiding systemic inflammation in healthy volunteers, and why PRTX007’s favorable profile is expected to correlate with efficacy in cancer therapy.
  • Date and Time: Wednesday, May 10 at 10 a.m.
  • ET

Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Greater Mauritania, TLR7, AACR, AE, Aes, Pharmacokinetics, IL-6, SAD, NK, Patient, MAD, Entrepreneurship, American Association for Cancer Research, Therapy, Headache, QOD, Vaccine, Pharmaceutical industry

In addition to assessing the clinical safety and tolerability of PRTX007, the study was designed to evaluate the pharmacokinetics of PRTX007 and identify the specific active dosing range for use in future cancer studies.

Key Points: 
  • In addition to assessing the clinical safety and tolerability of PRTX007, the study was designed to evaluate the pharmacokinetics of PRTX007 and identify the specific active dosing range for use in future cancer studies.
  • There were no systemic increases in proinflammatory factors observed for any dose range in the Phase 1 study.
  • Both the clinical characteristics and unique pattern of immune induction by PRTX007 support its use in combination with immune checkpoint inhibitors.
  • Primmune plans to conduct a future study evaluating PRTX007 in combination with a checkpoint inhibitor across the active doses identified in the Phase 1 study for the potential treatment of solid tumors.

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, TLR7, AACR, Therapy, Annual general meeting, Pharmaceutical industry

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today announced the upcoming presentation of new clinical data from its Phase 1 study of PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today announced the upcoming presentation of new clinical data from its Phase 1 study of PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • The AACR Annual Meeting will be held in Orlando, Florida from April 14-19.
  • An e-poster will be made available online Friday, April 14 at 12 p.m.
  • ET.

Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant

Retrieved on: 
Tuesday, February 28, 2023
Hematology, University, Immune system, Journal, TLR7, SCT, UCLA, Research, Guanosine, Plasma protein binding, FDA, Prognosis, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fred Hutchinson Cancer Research Center, Hope, Haematopoietic system, Leukemia, Orphan drug, PNP, LR, Food, USD, Pharmaceutical industry

ZUG, Switzerland, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Laevoroc Immunology (‘Laevoroc’ or ‘the company’), a privately-owned, Swiss oncology development company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for LR 09, a novel metabolic immune checkpoint inhibitor, for the treatment of patients with haematological malignancies who are diagnosed with a relapse after allogeneic stem cell transplant (SCT).

Key Points: 
  • ZUG, Switzerland, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Laevoroc Immunology (‘Laevoroc’ or ‘the company’), a privately-owned, Swiss oncology development company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for LR 09, a novel metabolic immune checkpoint inhibitor, for the treatment of patients with haematological malignancies who are diagnosed with a relapse after allogeneic stem cell transplant (SCT).
  • LR 09 is a novel, rationally-designed form of the small molecule drug, Ulodesine, a purine nucleoside phosphorylase (PNP) inhibitor that was originally developed for the treatment of autoimmune and inflammatory disorders.
  • Recent research at the University of California, Los Angeles (UCLA), has revealed a novel, ground-breaking mode of action for LR 09 as a metabolic immune checkpoint inhibitor and supports its development for the treatment of patients experiencing relapse after allogeneic SCT.
  • Laevoroc Immunology acquired the commercial rights to LR 09 for new indications in 2021.

Apros Therapeutics to Present Interim Clinical Data from a Phase 1 Study Evaluating APR003 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting and World Vaccine & Immunotherapy Congress (WVIC) West Coast

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Interferon-stimulated gene, Journal, Private Securities Litigation Reform Act, Gastrointestinal tract, Cytokine, CA, JITC, Tissue, Cancer, Pharmacodynamics, Colorectal cancer, Alternative, Society for Immunotherapy of Cancer, Safety, Pharmacokinetics, CRC, TLR7, ISG15, MA, Therapy, Half-life, Immunotherapy, Annual general meeting, Infection, Aprus (Thrace), Boston Convention and Exhibition Center, Liver, Inflammation, Toxicity, SITC, Convention center, Patient, Interferon type I, PK, Pharmaceutical industry, Vaccine

Data will also be presented at the World Vaccine & Immunotherapy Congress, West Coast November 28th - December 1st in San Diego, CA.

Key Points: 
  • Data will also be presented at the World Vaccine & Immunotherapy Congress, West Coast November 28th - December 1st in San Diego, CA.
  • APR003 was safely administered and rapidly absorbed with a pulsatile PK profile.
  • Pharmacodynamic analysis revealed that upon weekly dosing, APR003 elicited robust Interferon-alpha, Interferon-gamma inducible protein 10 (IP-10), and Interferon Stimulated Gene 15 (ISG15) responses, suggesting strong immune priming.
  • Apros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.